Capsazepine
CAS: 138977-28-3
Rif. 3D-FC19673
1mg | Fuori produzione | ||
2mg | Fuori produzione | ||
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione |
Informazioni sul prodotto
- N-[2-(4-Chlorophenyl)ethyl]-1,3,4,5-tetrahydro-7,8-dihydroxy-2H-2-benzazepine-2-carbothioamide
- 2H-2-Benzazepine-2-carbothioamide, N-[2-(4-chlorophenyl)ethyl]-1,3,4,5-tetrahydro-7,8-dihydroxy-
- Capsazepine Synthetic Analog Of C
- N-[2-(4-Chlorophenyl)Ethyl]-1,3,4,5-Tetrahydro-7,8-Dihydroxy-2H-2-Benzazepine-2-Carbothioamide
- N-[2-(4-chlorophenyl)ethyl]-7,8-dihydroxy-1,3,4,5-tetrahydro-2H-2-benzazepine-2-carbothioamide
- N-[2-(Chlorophenyl)Ethyl]-1,3,4,5-Tetrahydro-7,8-Dihydroxy-2H-2-Benzazepine-2-Carbothioamide
Capsazepine is a capsaicin antagonist that blocks the activation of the vanilloid receptor TRPV1. Capsazepine is used in the treatment of bowel disease and nonsteroidal anti-inflammatory drug-induced ulcers. This drug has significant cytotoxicity, as seen by its polymerase chain reaction inhibition in human colon cancer cells. It can also induce apoptosis and inhibit cancer cell growth, which may be due to its ability to block tumor necrosis factor-α (TNF-α) induced inflammation. Capsazepine has been shown to have biochemical properties similar to those of other inhibitors of TNF-α, such as myocardial infarct and toll-like receptor 4 (TLR4) signaling pathways.